Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Zaja

Showing results (21-30 of 145) with videos related to

Pageof 15
Sort By:
Leukemia & Lymphoma|January 24, 2004
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseasesFrancesco Zaja, Nicola Vianelli, Alessandra Sperotto, et al.
Haematologica|February 8, 2006
Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcomeCristina Skert, Francesca Patriarca, Alessandra Sperotto, et al.
European Journal of Haematology|September 17, 2013
Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemiaWilma Barcellini, Francesco Zaja, Anna Zaninoni, et al.
European Journal of Haematology|May 31, 2008
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up resultsMarta Medeot, Francesco Zaja, Nicola Vianelli, et al.
Frontiers in Oncology|May 14, 2021
Case Report: Cardiac Involvement by Lymphoma: Rare but Heterogeneous Condition With Challenging BehaviorsElisa Lucchini, Marco Merlo, Mario Ballerini, et al.
Advances in Clinical Pathology : the Official Journal of Adriatic Society of Pathology|September 17, 2009
Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patientsAlessandra Sperotto, Daniela Damiani, Francesco Zaja, et al.
Annals of Hematology|April 18, 2013
Bendamustine salvage therapy for T cell neoplasmsFrancesco Zaja, Luca Baldini, Andrés J M Ferreri, et al.
Mabs|August 13, 2013
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsJosée Golay, Gianpietro Semenzato, Alessandro Rambaldi, et al.
Blood|February 1, 2003
Efficacy and safety of rituximab in type II mixed cryoglobulinemiaFrancesco Zaja, Salvatore De Vita, Cesare Mazzaro, et al.
Therapeutic Drug Monitoring|November 25, 2005
Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settingsMario B Regazzi, Isabella Iacona, Maria Antonietta Avanzini, et al.
Pageof 15

Showing results (21-30 of 145) with videos related to

Sort By:
Pageof 15
Leukemia & Lymphoma|January 24, 2004
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseasesFrancesco Zaja, Nicola Vianelli, Alessandra Sperotto, et al.
Haematologica|February 8, 2006
Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcomeCristina Skert, Francesca Patriarca, Alessandra Sperotto, et al.
European Journal of Haematology|September 17, 2013
Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemiaWilma Barcellini, Francesco Zaja, Anna Zaninoni, et al.
European Journal of Haematology|May 31, 2008
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up resultsMarta Medeot, Francesco Zaja, Nicola Vianelli, et al.
Frontiers in Oncology|May 14, 2021
Case Report: Cardiac Involvement by Lymphoma: Rare but Heterogeneous Condition With Challenging BehaviorsElisa Lucchini, Marco Merlo, Mario Ballerini, et al.
Advances in Clinical Pathology : the Official Journal of Adriatic Society of Pathology|September 17, 2009
Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patientsAlessandra Sperotto, Daniela Damiani, Francesco Zaja, et al.
Annals of Hematology|April 18, 2013
Bendamustine salvage therapy for T cell neoplasmsFrancesco Zaja, Luca Baldini, Andrés J M Ferreri, et al.
Mabs|August 13, 2013
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsJosée Golay, Gianpietro Semenzato, Alessandro Rambaldi, et al.
Blood|February 1, 2003
Efficacy and safety of rituximab in type II mixed cryoglobulinemiaFrancesco Zaja, Salvatore De Vita, Cesare Mazzaro, et al.
Therapeutic Drug Monitoring|November 25, 2005
Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settingsMario B Regazzi, Isabella Iacona, Maria Antonietta Avanzini, et al.
Pageof 15